Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ciro Celsa

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
Med (New York, N.Y.)|February 15, 2025
The VIVID-1 study: A novel methodological approach provides further evidence of efficacy of selective IL-23 inhibition in Crohn's diseaseMaria Cappello, Ciro Celsa
Alimentary Pharmacology & Therapeutics|February 10, 2021
Editorial: proton pump inhibitor use in cirrhosis-a piece of the puzzleCiro Celsa, Calogero Cammà
Journal of Hepatology|October 3, 2022
Expert opinion vs. meta-analysis: To be or not to be?Calogero Cammà, Marco Enea, Ciro Celsa
Journal of Hepatology|March 14, 2024
Reply to: "irLI or not irLI: That is the question"Ciro Celsa, Giuseppe Cabibbo, David James Pinato
Journal of Hepatology|October 19, 2025
Reply to: "A role for non-selective beta-blockers in preventing liver decompensation in patients with hepatocellular carcinoma undergoing systemic therapy": Advancing clinical trial design and patient care in hepatocellular carcinomaCiro Celsa, David James Pinato, Giuseppe Cabibbo
Hepatology (Baltimore, Md.)|December 26, 2024
Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Giuseppe Cabibbo, David J Pinato
Hepatology (Baltimore, Md.)|January 10, 2023
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moonGiuseppe Cabibbo, Ciro Celsa, Eleonora Alimenti, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 24, 2018
Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?Giuseppe Cabibbo, Ciro Celsa, Calogero Cammà, et al.
Current Pharmaceutical Design|May 22, 2020
The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver DiseaseGrazia Pennisi, Ciro Celsa, Antonina Giammanco, et al.
Gastrointestinal Endoscopy|June 27, 2020
Through-the-needle biopsy of pancreatic cystic lesions: stronger evidences of higher diagnostic yield compared with cytologyMatteo Tacelli, Ciro Celsa, Paolo Giorgio Arcidiacono, et al.
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
Med (New York, N.Y.)|February 15, 2025
The VIVID-1 study: A novel methodological approach provides further evidence of efficacy of selective IL-23 inhibition in Crohn's diseaseMaria Cappello, Ciro Celsa
Alimentary Pharmacology & Therapeutics|February 10, 2021
Editorial: proton pump inhibitor use in cirrhosis-a piece of the puzzleCiro Celsa, Calogero Cammà
Journal of Hepatology|October 3, 2022
Expert opinion vs. meta-analysis: To be or not to be?Calogero Cammà, Marco Enea, Ciro Celsa
Journal of Hepatology|March 14, 2024
Reply to: "irLI or not irLI: That is the question"Ciro Celsa, Giuseppe Cabibbo, David James Pinato
Journal of Hepatology|October 19, 2025
Reply to: "A role for non-selective beta-blockers in preventing liver decompensation in patients with hepatocellular carcinoma undergoing systemic therapy": Advancing clinical trial design and patient care in hepatocellular carcinomaCiro Celsa, David James Pinato, Giuseppe Cabibbo
Hepatology (Baltimore, Md.)|December 26, 2024
Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Giuseppe Cabibbo, David J Pinato
Hepatology (Baltimore, Md.)|January 10, 2023
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moonGiuseppe Cabibbo, Ciro Celsa, Eleonora Alimenti, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 24, 2018
Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?Giuseppe Cabibbo, Ciro Celsa, Calogero Cammà, et al.
Current Pharmaceutical Design|May 22, 2020
The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver DiseaseGrazia Pennisi, Ciro Celsa, Antonina Giammanco, et al.
Gastrointestinal Endoscopy|June 27, 2020
Through-the-needle biopsy of pancreatic cystic lesions: stronger evidences of higher diagnostic yield compared with cytologyMatteo Tacelli, Ciro Celsa, Paolo Giorgio Arcidiacono, et al.
Pageof 12